Tags

Type your tag names separated by a space and hit enter

Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease.
Arch Neurol. 2005 Apr; 62(4):554-60.AN

Abstract

BACKGROUND

Deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) has been reported to relieve motor symptoms and levodopa-induced dyskinesia in patients with advanced Parkinson disease (PD). Although it has been suggested that stimulation of the STN may be superior to stimulation of the GPi, comparative trials are limited.

OBJECTIVE

To extend our randomized, blinded pilot comparison of the safety and efficacy of STN and GPi stimulation in patients with advanced PD.

DESIGN

This study represents the combined results from our previously published, randomized, blinded, parallel-group pilot study and additional patients enrolled in our single-center extension study.

SETTING

Oregon Health and Science University in Portland.Patients Twenty-three patients with idiopathic PD, levodopa-induced dyskinesia, and response fluctuations were randomized to implantation of bilateral GPi or STN stimulators. Patients and evaluating clinicians were blinded to stimulation site. All patients were tested preoperatively while taking and not taking medications and after 3, 6, and 12 months of DBS.

MAIN OUTCOME MEASURES

Postoperatively, response of symptoms to DBS, medication, and combined medication and DBS was evaluated. Twenty patients (10 in the GPi group and 10 in the STN group) completed 12-month follow-up.

RESULTS

Off-medication Unified Parkinson's Disease Rating Scale motor scores were improved after 12 months of both GPi and STN stimulation (39% vs 48%). Bradykinesia tended to improve more with STN than GPi stimulation. No improvement in on-medication function was observed in either group. Levodopa dose was reduced by 38% in STN stimulation patients compared with 3% in GPi stimulation patients (P = .08). Dyskinesia was reduced by stimulation at both GPi and STN (89% vs 62%). Cognitive and behavioral complications were observed only in combination with STN stimulation.

CONCLUSION

Stimulation of either the GPi or STN improves many features of advanced PD. It is premature to exclude GPi as an appropriate target for DBS in patients with advanced disease.

Authors+Show Affiliations

Department of Neurological Surgery, Oregon Health and Science University, Portland, OR 97201, USA. andersov@ohsu.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15824252

Citation

Anderson, Valerie C., et al. "Pallidal Vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease." Archives of Neurology, vol. 62, no. 4, 2005, pp. 554-60.
Anderson VC, Burchiel KJ, Hogarth P, et al. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol. 2005;62(4):554-60.
Anderson, V. C., Burchiel, K. J., Hogarth, P., Favre, J., & Hammerstad, J. P. (2005). Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Archives of Neurology, 62(4), 554-60.
Anderson VC, et al. Pallidal Vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease. Arch Neurol. 2005;62(4):554-60. PubMed PMID: 15824252.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. AU - Anderson,Valerie C, AU - Burchiel,Kim J, AU - Hogarth,Penelope, AU - Favre,Jacques, AU - Hammerstad,John P, PY - 2005/4/13/pubmed PY - 2005/5/11/medline PY - 2005/4/13/entrez SP - 554 EP - 60 JF - Archives of neurology JO - Arch Neurol VL - 62 IS - 4 N2 - BACKGROUND: Deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) has been reported to relieve motor symptoms and levodopa-induced dyskinesia in patients with advanced Parkinson disease (PD). Although it has been suggested that stimulation of the STN may be superior to stimulation of the GPi, comparative trials are limited. OBJECTIVE: To extend our randomized, blinded pilot comparison of the safety and efficacy of STN and GPi stimulation in patients with advanced PD. DESIGN: This study represents the combined results from our previously published, randomized, blinded, parallel-group pilot study and additional patients enrolled in our single-center extension study. SETTING: Oregon Health and Science University in Portland.Patients Twenty-three patients with idiopathic PD, levodopa-induced dyskinesia, and response fluctuations were randomized to implantation of bilateral GPi or STN stimulators. Patients and evaluating clinicians were blinded to stimulation site. All patients were tested preoperatively while taking and not taking medications and after 3, 6, and 12 months of DBS. MAIN OUTCOME MEASURES: Postoperatively, response of symptoms to DBS, medication, and combined medication and DBS was evaluated. Twenty patients (10 in the GPi group and 10 in the STN group) completed 12-month follow-up. RESULTS: Off-medication Unified Parkinson's Disease Rating Scale motor scores were improved after 12 months of both GPi and STN stimulation (39% vs 48%). Bradykinesia tended to improve more with STN than GPi stimulation. No improvement in on-medication function was observed in either group. Levodopa dose was reduced by 38% in STN stimulation patients compared with 3% in GPi stimulation patients (P = .08). Dyskinesia was reduced by stimulation at both GPi and STN (89% vs 62%). Cognitive and behavioral complications were observed only in combination with STN stimulation. CONCLUSION: Stimulation of either the GPi or STN improves many features of advanced PD. It is premature to exclude GPi as an appropriate target for DBS in patients with advanced disease. SN - 0003-9942 UR - https://www.unboundmedicine.com/medline/citation/15824252/Pallidal_vs_subthalamic_nucleus_deep_brain_stimulation_in_Parkinson_disease_ L2 - https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneur.62.4.554 DB - PRIME DP - Unbound Medicine ER -